Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | ADA | P00813 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29174993 | 0.84 | PDE2A (0.36) | PDE2APDE1CSMN1; SMN2NPC1RAB9A | |
| SCHEMBL29174941 | 0.83 | PDE10A (0.47) | PDE10APDE2A | |
| SCHEMBL30095656 | 0.83 | PDE10A (0.47) | PDE10APDE2A | |
| SCHEMBL29174833 | 0.80 | PDE1C (0.34) | PDE10APDE1CSMN1; SMN2NPC1RAB9A | |
| SCHEMBL31194523 | 0.79 | PDE2A (0.42) | PDE10APDE2APDE1CSMN1; SMN2NPC1 | |
| SCHEMBL174841 | 0.79 | PDE2A (0.42) | PDE10APDE2APDE1CSMN1; SMN2NPC1 | |
| SCHEMBL4698941 | 0.77 | PDE2A (0.42) | PDE10APDE2A | |
| SCHEMBL29174904 | 0.76 | PDE10A (0.43) | PDE10A | |
| SCHEMBL30095904 | 0.76 | PDE10A (0.43) | PDE10A | |
| SCHEMBL29174864 | 0.76 | KDM4E (0.50) | PDE10APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270750-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-08-15 | — | — | US | disclosed |
| EP-4346806-A2 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | Biocryst Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117529315-A | Imidazole-containing ALK2 kinase inhibitors | 生物水晶制药公司 | 2024-02-06 | — | — | CN | disclosed |
| WO-2022251188-A2 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270750-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | PDE10A 822/4885PDE2A 370/4885PDE1C 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.